Homewood Research Institute, Guelph, ON, Canada.
Homewood Research Institute, Guelph, ON, Canada.
J Subst Abuse Treat. 2020 Dec;119:108127. doi: 10.1016/j.jsat.2020.108127. Epub 2020 Sep 16.
Clinicians need a broad spectrum measurement of psychoactive substance craving (i.e., alcohol and/or drug) to assess collective treatment effects, especially in the context of polysubstance use. In three separate studies, we investigated the psychometric properties of an adapted version of the Penn Alcohol Craving Scale (PACS), designed to measure broad range substance craving.
In Study One, we examined the latent factor structure for craving, as well as concurrent validity with measures of frequency and severity of substance use. In Study Two, we examined the short-term test-retest reliability. In Study Three, we examined the long-term sensitivity to treatment effects at 12 month postdischarge.
An inpatient SUD program in Guelph, Ontario, Canada.
Adult patients receiving treatment for SUD: Study One, n = 971; Study Two, n = 35; Study Three, n = 191.
We used an adapted version of the PACS, termed the Aggregated Drug Craving Scale (ADCS), and measures of substance use frequency, severity, and abstinence.
In Study One, confirmatory factor analysis supported the unidimensional structure of the craving scale (CFI: 0.994, RMSEA: 0.071, SRMR: 0.010). In addition, statistically significant, medium effect size associations provided evidence of concurrent validity with measures of substance use frequency and severity (CFI = 0.992; RMSEA = 0.054; SRMR = 0.015). In Study Two, the ADCS demonstrated good agreement over two time points (ICC = 0.82), exhibiting acceptable short-term retest reliability. In Study 3, the mean craving score decreased significantly from 19.6 at baseline to 7.5 at 12-month follow-up (t = -18.48, p < 0.001), demonstrating an ability to detect long-term sensitivity to treatment effects (Cohen's d = -1.54).
Together, these findings provide initial support for a concise, broad-spectrum measure of aggregated drug cravings among an SUD treatment population.
临床医生需要对心理活性物质的渴求（即酒精和/或药物）进行广泛的测量，以评估整体治疗效果，特别是在多药物使用的情况下。在三项独立的研究中，我们研究了经过改编的宾夕法尼亚酒精渴求量表（PACS）的心理计量学特性，该量表旨在测量广泛的物质渴求。
在研究一中，我们考察了渴求的潜在因素结构，以及与物质使用频率和严重程度的测量方法的同时效度。在研究二中，我们考察了短期重测信度。在研究三中，我们考察了 12 个月出院后的治疗效果的长期敏感性。
加拿大安大略省圭尔夫的一个物质使用障碍（SUD）住院治疗项目。
接受 SUD 治疗的成年患者：研究一，n=971；研究二，n=35；研究三，n=191。
我们使用了经过改编的 PACS 版本，称为综合药物渴求量表（ADCS），以及物质使用频率、严重程度和戒断的测量方法。
在研究一中，验证性因素分析支持了渴求量表的单维结构（CFI：0.994，RMSEA：0.071，SRMR：0.010）。此外，具有统计学意义的中等效应量关联为物质使用频率和严重程度的测量方法提供了同时效度的证据（CFI=0.992；RMSEA=0.054；SRMR=0.015）。在研究二中，ADCS 在两个时间点上表现出良好的一致性（ICC=0.82），表现出可接受的短期重测信度。在研究 3 中，从基线的 19.6 分显著下降到 12 个月随访时的 7.5 分（t=-18.48，p<0.001），表明能够检测到对治疗效果的长期敏感性（Cohen's d=-1.54）。
总的来说，这些发现初步支持了一种简明、广泛的综合药物渴求测量方法，适用于 SUD 治疗人群。
